Heyholder
‹ Activism Filings

MYUNGIN PHARM.CO., LTD Q3 operating profit KRW 27.1 billion on sales of KRW 76.8 billion

MYUNGIN PHARM.CO., LTD· Periodic Report

AI summary · Not investment advice

Myungin Pharm sold KRW 76.8 billion worth in Q3 and earned KRW 27.1 billion from its main business, up 23.5% from a year earlier and down 2.0% from the prior quarter.

Operating profit · 3 months

KRW 27.1 billion

Key facts

Revenue (3 months)
KRW 76.8 billion
Net income (3 months)
KRW 21.2 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 72.7 billion
Revenue (year to date)
KRW 225.1 billion
Operating profit (prior-year 3 months)
KRW 21.9 billion
Operating profit (year to date)
KRW 79.8 billion
Net income (prior-year 3 months)
KRW 18.5 billion
Net income (year to date)
KRW 68.3 billion

Commentary

AI commentary · Not investment advice

What happened

Myungin Pharm filed its quarterly report with consolidated results for the third quarter. Sales for the latest 3 months were KRW 76.84 billion. That is 5.7% above the same 3 months a year earlier (KRW 72.70 billion) and 1.0% above the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was KRW 27.06 billion. That is 23.5% above a year earlier (KRW 21.91 billion) and 2.0% below the previous quarter. Net income (final profit after taxes and other costs) was KRW 21.22 billion. That is 14.4% above a year earlier (KRW 18.55 billion) and 12.8% below the previous quarter.

What changes for shareholders

For the year to date, from January 1 to September 30, sales were KRW 225.08 billion. Operating profit was KRW 79.78 billion and net income was KRW 68.27 billion.

Comments

No comments yet

Comments from shareholders will appear here.